File photo used for representational purpose only.
| Photo Credit: The Hindu
An active pharmaceutical ingredients manufacturing facility of Laurus Labs in Visakhapatnam that received an observation post an inspection by United States Food and Drug Administration earlier this year has been issued establishment inspection report by the regulator.
The company has received the EIR, the drugmaker said in a filing on Tuesday (April 16, 2025). The U.S. FDA had inspected the API manufacturing facility Unit–4 in Atchutapuram, Anakapalli district from January 27-31 and issued a Form 483 with one observation.
Published – April 16, 2025 10:18 am IST
